Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 2/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | MTOR | P42345 | 4/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | GOT1 | P17174 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681685 | 0.91 | MEN1 (0.68) | MEN1KMT2ACNR1EPHX2MTOR | |
| SCHEMBL11625998 | 0.88 | SMN1; SMN2 (0.58) | MEN1KMT2ACNR1EPHX2MTOR | |
| SCHEMBL28728293 | 0.87 | MEN1 (0.77) | MEN1KMT2ACNR1EPHX2MTOR | |
| SCHEMBL598010 | 0.84 | CNR1 (0.66) | MEN1KMT2ACNR1EPHX2HTT | |
| SCHEMBL11626001 | 0.84 | MEN1 (0.52) | MEN1KMT2ACNR1EPHX2MTOR | |
| SCHEMBL28728205 | 0.83 | MEN1 (0.70) | MEN1KMT2ACNR1EPHX2MTOR | |
| SCHEMBL13737287 | 0.82 | MAPT (0.64) | MEN1KMT2ACNR1LMNAHTT | |
| SCHEMBL30797249 | 0.82 | MAPT (0.64) | MEN1KMT2ACNR1LMNAHTT | |
| SCHEMBL8244860 | 0.81 | CNR1 (0.63) | MEN1KMT2ACNR1LMNACA12 | |
| SCHEMBL28729179 | 0.80 | EPHX2 (1.00) | MEN1KMT2AEPHX2MTORNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244817-A1 | SUBSTITUTED PIPERIDINES AS CK1A DEGRADERS | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11236053-B2 | NADPH oxidase inhibitors and uses thereof | EMORY UNIVERSITY (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200270214-A1 | NADPH Oxidase Inhibitors and Uses Thereof | UNIV EMORY (US) | 2020-08-27 | — | — | US | disclosed |
| WO-2019023448-A1 | NADPH OXIDASE INHIBITORS AND USES THEREOF | EMORY UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| US-8334313-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1542667-B1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7902241-B2 | 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes | PTC THERAPEUTICS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-7405233-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | MEN1 2666/4885KMT2A 1499/4885CNR1 1801/4885 |
| US-20200270214-A1 | NADPH Oxidase Inhibitors and Uses Thereof | NOX1, NOX3, NOX5 | MEN1 4554/4885KMT2A 2871/4885CNR1 3038/4885 |
| US-11236053-B2 | NADPH oxidase inhibitors and uses thereof | NOX1, NOX3, NOX5 | MEN1 4554/4885KMT2A 2871/4885CNR1 3038/4885 |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | MEN1 2666/4885KMT2A 1499/4885CNR1 1801/4885 |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | MEN1 2666/4885KMT2A 1499/4885CNR1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.